Dr. Million Molla Sisay is an Ethiopian medical professional and researcher associated with St. Peter’s Specialized Hospital in Addis Ababa. Published scientific literature identifies him with the hospital's Research and Evidence Generation Directorate, where he has contributed to research addressing tuberculosis, multidrug-resistant TB, HIV, and related clinical conditions.

His professional work is particularly relevant to Ethiopia's national tuberculosis program and the specialized services provided at St. Peter’s. The hospital is a major referral center for tuberculosis and has played a central role in the country's management of drug-resistant TB. Recent research continues to describe St. Peter’s as a national referral center and major treatment-initiation facility for MDR-TB.

Dr. Million has contributed to peer-reviewed research examining clinical conditions among patients receiving treatment at St. Peter’s. A 2021 study published in Infection and Drug Resistance investigated thyroid abnormalities among patients with multidrug-resistant tuberculosis attending St. Peter’s Specialized Hospital. The article lists Million Molla Sisay among its authors and identifies his affiliation as the hospital's Research and Evidence Generation Directorate.

His research contribution illustrates the importance of monitoring patients receiving complex TB treatment. Drug-resistant TB regimens can involve multiple medications and require clinical monitoring for adverse effects and associated medical conditions. Research examining such complications can help healthcare professionals understand patient needs and improve treatment monitoring.

Dr. Million has also contributed to research evaluating treatment outcomes for multidrug-resistant tuberculosis in Ethiopia. A study published in BMJ Open examined national treatment outcomes and predictors of death and treatment failure among patients receiving MDR-TB treatment. The publication identifies Million Molla Sisay with the Research and Evidence Generation Directorate at Saint Peter’s Specialized Hospital.

The hospital's research environment provides an important link between clinical services and evidence generation. St. Peter’s combines specialized TB treatment with research, training, laboratory services, and public-health activities. This environment supports studies designed to address practical challenges in tuberculosis management.

For patients seeking treatment for TB or drug-resistant TB in Ethiopia, specialist care may involve several stages, including diagnostic confirmation, drug-susceptibility testing, clinical assessment, treatment selection, monitoring, and follow-up. Patients should bring previous laboratory results, microbiological testing, imaging, treatment history, and medication records when possible.

TB and HIV can also occur together, requiring coordinated management. Research involving St. Peter’s has examined the relationship between tuberculosis, HIV, treatment outcomes, and patient characteristics. Such work is important because coexisting conditions may influence treatment planning and clinical monitoring.

Dr. Million's documented role is especially relevant to research and evidence generation. Directory publishers should distinguish between his research affiliation and a claim that he provides routine clinical consultations. The available publications establish his association with St. Peter’s Specialized Hospital and his contribution to TB-related research, but they do not provide a sufficiently detailed current clinical job description.

St. Peter’s remains an important institution for tuberculosis care in Ethiopia. A 2026 study describes the hospital as a longstanding specialized TB referral center providing comprehensive MDR-TB services since 2009.

For international patients, treatment planning should be based on current clinical assessment rather than research affiliation alone. Patients should confirm which specialists and services are currently available and whether a particular physician is accepting consultations.